Since TRAIL was first discovered for its ability to induce apoptosis in cancer cells without affecting non-transformed cell populations (Wiley et al., 1995; Pitti et al., 1996), TRAIL receptors, in particular DR5, have been an attractive therapeutic target for cancer over the past 30 years (von Karstedt et al., 2017). Here, TNFRSF10B is linked to cancer.